Presentation of the Effects of QGC606 in an Experimental Model of Heart Failure at the Annual Congress of the European Society of Cardiology
Quantum Genomics, a biopharmaceutical firm listed as QNNTF, announced it will present preclinical study results of its drug QGC606 for heart failure at the European Society of Cardiology annual congress on August 28, 2021. The study, which examines QGC606's effects on cardiac function after myocardial infarction, was conducted in collaboration with INSERM. This innovative prodrug targets resistant hypertension and heart failure, a condition that affects many patients. Quantum Genomics aims to develop breakthrough treatments based on over 20 years of research.
- Presentation of preclinical study results of QGC606, indicating ongoing development in heart failure treatments.
- QGC606 targets resistant hypertension and heart failure, addressing unmet medical needs.
- None.
PARIS, July 05, 2021 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), biopharmaceutical company specializing in the development of a new class of drugs acting directly on the brain to treat resistant high blood pressure and heart failure, will present results of a preclinical study of QGC606 in heart failure after myocardial infarction. The oral presentation will be delivered by Dr. Catherine Llorens-Cortes during the "Late Breaking Basic & Translational Science" sessions of the annual congress of the European Society of Cardiology.
QGC606 is a novel prodrug of a potent aminopeptidase A inhibitor selected by Quantum Genomics. The study evaluating the effects of QGC606 on cardiac function in mice after myocardial infarction induced by ligation of the left coronary artery, was carried out in the INSERM laboratory "Central Neuropeptides in the Regulation of Body Fluid Homeostasis and Cardiovascular Functions" led by Dr. Catherine Llorens-Cortes at the Collège de France in collaboration with Quantum Genomics.
Details of the oral presentation
Title: Comparison of QGC606, a novel orally active brain-penetrating aminopeptidase A inhibitor prodrug with firibastat and ramipril for treating heart failure following myocardial infarction
Session: Late Breaking Basic & Translational Science
Chairperson: Stefanie Dimmeler (Goethe University Hospital – Frankfurt, Germany)
Date: August 28th 2021
Time: 9:30 – 10:15 am CET
About Quantum Genomics
Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on 20 years of academic research from the Paris-Descartes University and the laboratory directed by Dr. Catherine Llorens-Cortes at the Collège de France (French National Institute of Health and Medical Research (INSERM)/ the Scientific Centre for National Research (CNRS)). The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around
Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC) and trades on the OTCQX Best Market in the United States (symbol: QNNTF).
For more information, please visit www.quantum-genomics.com, or follow us on Twitter and LinkedIn
Contact
| Quantum Genomics | |
| Contact@quantum-genomics.fr | |
| So Bang (Europe) | |
| Financial and Media communication Quantum-genomics@so-bang.fr | |
| LifeSci (USA) | |
| Mike Tattory Media Relations and Scientific Communications +1 (609) 802-6265 | mtattory@lifescicomms.com |
FAQ
What is QGC606 and its significance for Quantum Genomics?
When will Quantum Genomics present the QGC606 study results?
Where can I find more information on Quantum Genomics and its developments?
What does the presentation at the European Society of Cardiology signify for QNNTF?
